[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BiopharmIQ by Amp [@BiopharmIQ](/creator/twitter/BiopharmIQ) on x 25.9K followers Created: 2025-07-12 18:32:23 UTC 🧬 Biopharma 𝕏 Weekly Recap 📝 Interesting posts/ppl to check out! 👇 @BowTiedBiotech 1/ 🫁 Merck’s $10B Verona Bet: A Biotech Thread » @Andre_AGTC $VRNA aquisition has positive effect on bios which are potential BO candidates $MDGL $MIRM $BBIO $SRRK $CRNX » @JacobPlieth $VRNA’s Enfisentirine Composition Patent Expired in 2020 — Not a Concern for $MRK? » @LifeSciVC $MRK will acquire Verona Pharma $VRNA for $10B. Fun bit of biotech history... » @A_May_MD Parallels Between $NKTR and $VRNA: Early-Stage Setup, Market Potential, and Sentiment Dynamics » @doepke_michel $MDGL Positioned as Potential Takeover Target Following $BPMC and $VRNA Deals » @RNAiAnalyst $PRME has become a cult stock because the potential is limitless and they are far ahead of the prime editing game, including IP. » @GeneInvesting A quick look at how gene therapies have fared commercially thus far… $NTLA $CRSP $BEAM $PRME $XBI » @S_Gallagher23 🚀 Gene Therapy Delivery: Why LNPs Are Still on Top! » @yaireinhorn $CRSP Named to TIME100 List Following Landmark FDA Approval for CRISPR Therapy » @MeadowCapital $VKTX Updated July 2025 Corporate presentation. » @princetongb $VKTX Approaches 52-Week High Ahead of VK2735 Oral Data; Potential Upside and M&A Speculation » @Pharmdca $VKTX: High Short Interest, Key Oral Data Ahead, Breakout from Consolidation » @Biotech2k1 Biotech Investing: Balancing High Failure Rates, Management Risk, and Buyout Opportunities » @learnbiotech Here's some data for #investors when trying to benchmark the costs of pivotal clinical trials (2015-2017) » @Gantosj No more hiding for #biotech companies $XBI The FDA today published more than XXX CRL decision! » @BiopharmIQ 🎯 Ph2 & Ph3 readouts in Q3 2025... » @HOThomasWPhelps Updated $NKTR Phase X AD Data Table with $APGE Ph2a Results for Comparison » @shelbynewsad XX bio companies on the edge of legality and ethics » @paras_biotech Therapeutic and strategic analysis of biopharma companies trading below cash »  XXXXXX engagements  **Related Topics** [alot](/topic/alot) [$vrnas](/topic/$vrnas) [$mirm](/topic/$mirm) [$vrna](/topic/$vrna) [$10b](/topic/$10b) [$mdgl](/topic/$mdgl) [$bbio](/topic/$bbio) [$srrk](/topic/$srrk) [Post Link](https://x.com/BiopharmIQ/status/1944102553324863581)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BiopharmIQ by Amp @BiopharmIQ on x 25.9K followers
Created: 2025-07-12 18:32:23 UTC
🧬 Biopharma 𝕏 Weekly Recap 📝
Interesting posts/ppl to check out! 👇
@BowTiedBiotech 1/ 🫁 Merck’s $10B Verona Bet: A Biotech Thread »
@Andre_AGTC $VRNA aquisition has positive effect on bios which are potential BO candidates $MDGL $MIRM $BBIO $SRRK $CRNX »
@JacobPlieth $VRNA’s Enfisentirine Composition Patent Expired in 2020 — Not a Concern for $MRK? »
@LifeSciVC $MRK will acquire Verona Pharma $VRNA for $10B. Fun bit of biotech history... »
@A_May_MD Parallels Between $NKTR and $VRNA: Early-Stage Setup, Market Potential, and Sentiment Dynamics »
@doepke_michel $MDGL Positioned as Potential Takeover Target Following $BPMC and $VRNA Deals »
@RNAiAnalyst $PRME has become a cult stock because the potential is limitless and they are far ahead of the prime editing game, including IP. »
@GeneInvesting A quick look at how gene therapies have fared commercially thus far… $NTLA $CRSP $BEAM $PRME $XBI »
@S_Gallagher23 🚀 Gene Therapy Delivery: Why LNPs Are Still on Top! »
@yaireinhorn $CRSP Named to TIME100 List Following Landmark FDA Approval for CRISPR Therapy »
@MeadowCapital $VKTX Updated July 2025 Corporate presentation. »
@princetongb $VKTX Approaches 52-Week High Ahead of VK2735 Oral Data; Potential Upside and M&A Speculation »
@Pharmdca $VKTX: High Short Interest, Key Oral Data Ahead, Breakout from Consolidation »
@Biotech2k1 Biotech Investing: Balancing High Failure Rates, Management Risk, and Buyout Opportunities »
@learnbiotech Here's some data for #investors when trying to benchmark the costs of pivotal clinical trials (2015-2017) »
@Gantosj No more hiding for #biotech companies $XBI The FDA today published more than XXX CRL decision! »
@BiopharmIQ 🎯 Ph2 & Ph3 readouts in Q3 2025... »
@HOThomasWPhelps Updated $NKTR Phase X AD Data Table with $APGE Ph2a Results for Comparison »
@shelbynewsad XX bio companies on the edge of legality and ethics »
@paras_biotech Therapeutic and strategic analysis of biopharma companies trading below cash »
XXXXXX engagements
Related Topics alot $vrnas $mirm $vrna $10b $mdgl $bbio $srrk